AtaiBeckley's Skyrocketing Stock: A Biotech Gamble

AtaiBeckleys stock surged 213% this year, outpacing the S&P 500, due to a merger with Beckley Psytech and recent clinical wins. The company, focused on psychedelic-based therapies, secured a $150M public offering, extending cash runway to 2029. Phase 2 trials for EMP-001 and expanded studies for VLS-01 are underway, with an $11.4M NIDA grant for opioid treatments. Wall Street analysts rate AtaiBeckley a strong buy, suggesting up to 284% upside.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.